Sun Pharma gets nod from South African regulator for generic semaglutide injection
Sun Pharmaceutical Industries has received approval from South African regulators to manufacture and market a generic version of the semaglutide injection. The drug, used for treating type 2 diabetes, will be available as a pre-filled, multi-dose injectable pen.
Why it matters
This expansion increases access to affordable diabetes medication in South Africa, addressing a growing public health challenge in the region.
Sun Pharmaceutical Industries Ltd. on Wednesday (July 15, 2026) said it has received approval from the South African regulator to manufacture and market a generic version of semaglutide injection in the country for treatment of adults with type 2 diabetes mellitus.
The article reports on corporate regulatory news in a factual, neutral manner without emotive language.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in